Alteogen (196170) reported animal-study results for its ALT-M5 obesity-treatment series, which it is developing for once-monthly dosing. The project is the first built on Alteogen's proprietary long-acting platform using its own conjugation technology. After a single subcutaneous injection, ALT-M5B4 produced a blood drug half-life of 68.1 hours, more than four times longer than retatrutide, Eli Lilly's triple-acting obesity drug candidate. In obese mice, twice-weekly injections of ALT-M5B418 reduced body weight by 55.3% from pre-dosing levels by day 21, compared with 49.0% for retatrutide and 21.0% for tirzepatide. Two weeks after treatment ended, ALT-M5B418 showed 34.7% weight regain, 9.5 percentage points below retatrutide's 44.2%. Alteogen presented the findings at ObesityWeek 2026, The Obesity Society's annual meeting, held in Washington, D.C., from the 14th to the 17th. The company said its platform combines multiple active ingredients and extends drug effectiveness by attaching a peptide and fatty acid conjugate to designated positions on an incretin-based fusion protein. Alteogen completed an international PCT patent application for the platform in September this year. CEO Jeon Tae-yeon said the company plans to expand the technology's applications following Hybrozyme and develop obesity treatments aimed at improving dosing convenience and weight maintenance.